Quantcast
Home > Quotes > HOOK

HOOKIPA Pharma Inc. Common Stock (HOOK) Quote & Summary Data

HOOK 
$12.59
*  
0.18
1.45%
Get HOOK Alerts
*Delayed - data as of Jan. 29, 2020 10:33 ET  -  Find a broker to begin trading HOOK now
Exchange:NASDAQ
Industry: Health Care
View:    HOOK Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 12.49 / $ 12.64
1 Year Target
18
Today's High / Low
$ 13.2858 / $ 12.41
Share Volume
6,063
50 Day Avg. Daily Volume
127,572
Previous Close
$ 12.41
52 Week High / Low
$ 14.76 / $ 6.06
Market Cap
319,892,864
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1

Intraday Chart

Shares Traded

Share Volume:
6,063
50 Day Avg. Daily Volume:
127,572

Trading Range

The current last sale of $12.59 is 107.76% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 13.2858 $ 14.76
 Low: $ 12.41 $ 6.06

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on our proprietary arenavirus platform that is designed to reprogram the body's immune system. We are using our "off-the-shelf" technologies, VaxWave and TheraT, to elicit directly within patients a powerful and durable response of antigen-specific killer T cells and antibodies, thereby activating essential immune defenses against infectious diseases and cancers. We believe that our technologies can meaningfully leverage the human immune system for prophylactic and therapeutic purposes by eliciting killer T cell response levels previously not achieved by other published immunotherapy approaches. Our lead infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.  ... More ...  



Risk Grade

Where does HOOK fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 12.41
Open Date:
Jan. 29, 2020
Close Price:
N/A
Close Date:
N/A


Consensus Recommendation

Analyst Info